Introduction: Dyspnoea is a common symptom of chronic obstructive pulmonary
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is characterized by persistent, usually progressive, airflow limitation [1] . COPD is a major cause of chronic morbidity and mortality, and presents a significant health challenge to payers across the world [2] . Despite being a preventable and treatable condition, COPD remains the third leading cause of death in the world [3] .
Dyspnoea, commonly known as breathlessness, is the most common symptom of COPD [4] . An increase in the level of dyspnoea is associated with an increase in fatigue and disability [5] . Dyspnoea has also been shown to be associated with a decrease in health-related quality of life [6] . However, cultural dimensions such as differences in language, race, ethnicity, and gender can influence the interpretation, quality, and intensity of reported dyspnoea [7] .
Whilst there is evidence showing that higher levels of dyspnoea are associated with an increased risk of a COPD exacerbation and mortality, there is limited evidence reporting the healthcare resource use (HCRU) among patients with differing levels of dyspnoea for the majority of countries [8, 9] . The objective of this study was to report the prevalence of moderate-to-severe dyspnoea and explore its humanistic and economic impact among patients with stable COPD across Europe and within individual European countries.
METHODS

Survey Design and Study Population
The Respiratory Disease-Specific Programme (DSP; Adelphi Real World) is a survey which collects key health outcomes information from patients diagnosed with COPD routinely consulting with their treating physicians. The full methodology of the DSP has been described previously [10] . Briefly, the DSP involves two key phases.
First, physicians are randomly selected by members of a local research agency in each country from public lists of healthcare professionals practicing in primary care or respiratory specialty as appropriate. These physicians are representative of the national population of physicians in terms of the physician's age, gender, and volume of activity, and are selected based on the quotas set by specialty type, geographical location, and number of patients with COPD currently being treated by them. For this study, data were combined from three separate Respiratory DSP surveys (2010, 2011, and 2012) The second phase involved physicians completing a standardized record form on the next six consenting patients diagnosed with COPD visiting their practice. Patients were selected by physicians based on consecutive sampling meeting the inclusion criteria of more than 40 years of age with history of smoking and diagnosis of airflow obstruction (COPD, emphysema, and/or chronic bronchitis) irrespective of their reason for physician visit such as repeat prescription, routine review, or an unscheduled consultation. The physician-completed record forms were completed only for the patients personally seen by the physician either during or immediately after the consultation by referring to patient records if needed. The physician-completed record form collected information on patient demographics, diagnostic history, and resource use in the past 12 months, current symptomatology and its impact on lifestyle, current and past treatments, treatment adherence, comorbidities [11] , and inhaler preference. Of these, data on resource use in the previous 12 months and the treatments patients were prescribed at the time of the survey were used in the present analysis.
Patients for whom a record form had been completed were then asked to complete a separate patient self-completion questionnaire by their physicians in clinic immediately after the physician visit. Representatives of the data collection agency ensured that patients completed their questionnaire without consulting the doctor, nursing staff, or any other individual.
Patients completed information on their COPD history, current symptomatology and its impact on general and COPD-specific health status, current treatments, and attitude towards COPD and its treatment. They also provided information on their health status at the time of the survey using a series of validated patient-reported outcome tools. This included disability due to dyspnoea captured using the modified Medical Research Council (mMRC) scale [12] , COPD-related health status using the COPD Assessment Test (CAT) [13] , general health status using the EuroQol questionnaire (3 levels; EQ-5D-3L) [14] , sleep quality based on the Jenkins Sleep Evaluation Questionnaire (JSEQ) [15] , and medication adherence using the Morisky Medication
Adherence Scale (MMAS) [16] .
Patient Inclusion Criteria
All patients included in this analysis were 40 years or older with a physician-confirmed diagnosis of airflow obstruction (COPD, emphysema, and/or chronic bronchitis). The patients were also required to have received at least one short-or long-acting COPD-specific treatment in the previous 12 months and were required to have a completed response to the mMRC scale question from the patient-completed questionnaire. The survey was conducted as a market research survey adhering to the ICC/ESOMAR international code on market and social research [17] and, therefore, ethical approval was not sought. Our study was a retrospective analysis of secondary data. Prior to volunteering to complete a questionnaire patients were asked to provide informed consent. The survey instructions described the purpose of the survey, why the respondent had been selected, and who might have access to the aggregated and anonymized dataset compiled.
Study Outcomes and Their Derivation
Patients were stratified by their level of dyspnoea at the time of the survey as no-to-mild (mMRC \2) or moderate-to-severe (mMRC C2) dyspnoea [1] . For each of these strata, patients' current humanistic burden was captured using CAT, JSEQ, and EQ-5D-3L.
Utilities were calculated using country-specific valuation sets of EQ-5D-3L. each resource use were derived for each country separately and were then converted to costs using appropriate unit cost for each event (see Table S1 in the supplementary material).
The unit costs were obtained from the literature or from a local expert specializing in health economics [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . If multiple costs were available, the lowest cost was used as a conservative estimate. 
Data Analysis
To report the burden of dyspnoea at the European level, patients across individual countries (France, Germany, Italy, Spain, and the UK) were pooled to form a single cohort. Further, the pooled cohort was weighted to ensure that the sample was more representative of the patient population. Weighting was based on an inverse probability of the patients' 12-month consultation rate. For patients with less than 12 months of consultation history, this weight was imputed based on their available consultations and the length of time the patient has been managed by the physician. Weightings were not applied to multivariate analyses.
Patients were described using demographic and healthcare utilization descriptors by their level of dyspnoea as no-to-mild (mMRC\2) and moderate-to-severe (mMRC C2). For each of these strata, the humanistic burden at the time of the survey was estimated using CAT, JSEQ, and EQ-5D-3L. The economic burden based on physician-reported HCRU also was estimated for the two dyspnoea-based cohorts. Statistical differences in humanistic and economic burden between groups (mMRC \2 vs. mMRC C2) were assessed using appropriate weighted regression models, whereby the type of regression model used depended on the type or distribution of the outcome variable. A significance level of 0.05 was used.
Finally, the two cohorts (mMRC \2 vs. mMRC C2) were matched using propensity score matching techniques [33] . Patients with moderate-to-severe dyspnoea were matched to a cohort of patients with no-to-mild dyspnoea with replacement to produce closely matched profiles [34, 35] . Covariates included in the matching were age, gender, smoking status, time since diagnosis, use of inhaled corticosteroid (ICS)-containing regimens including triple therapy, exacerbation history, number of concomitant conditions, and presence of severe cardiovascular comorbidity (Table 1) . Propensity scores were generated using logistic regression models. Standardized mean differences (SMDs) were used to assess covariate balance once the matching was
complete. An SMD between -10% and 10% (not inclusive) indicates adequate balance was achieved for that particular covariate [34] . To compare the total annual COPD management costs across two subgroups post-matching, the Abadie-Imbens (AI) standard error (SE) was estimated and the corresponding test statistic and P value were calculated [36, 37] . The effect of unobserved confounders on the P value was assessed using Rosenbaum sensitivity analyses [38] . In addition to the total cohort, this propensity matching analysis was also conducted in sub-cohorts of patients treated 
Prevalence of Dyspnoea
Nearly half of the patients (47.3%) reported a moderate-to-severe level of dyspnoea (mMRC C2). The frequency of dyspnoea ranged from 39.5% in France to 60.2% in the UK (Fig. 1) . This was validated using a sample of respondents, 40 years or older and receiving respiratory medications, collected as part of Health Survey of England [39] . The analysis showed that 56% of respondents indicated that their condition affects their stamina, breathing, or fatigue. Patients with dyspnoea were older, had a longer duration of diagnosed COPD, and more comorbidities in the combined cohort (Table 1) . A higher proportion of patients with dyspnoea were ex-smokers, currently received ICS-containing medications including triple therapy and suffered from a serious cardiovascular condition.
Association of Dyspnoea Level with Health Status
Moderate-to-severe dyspnoea was significantly 
P\0.0001).
These observations were consistent across all countries surveyed (see Table S3 in the supplementary material).
Association of Dyspnoea Level with HCRU
Among the moderate-to-severe dyspnoeic patients, 597 (50.6%) had at least one moderate exacerbation and 389 (34.7%) had at least one severe exacerbation in the previous 12 months. The corresponding proportions for patients with no-to-mild dyspnoea were 30.0% and 9.5%, respectively. In addition, higher proportions of patients in the moderate-to-severe dyspnoeic group had at least one emergency department visit leading to hospitalization (26.1% vs. 5.8%; P\0.0001) or not leading to hospitalization (14.7% vs. 3.9%; P\0.0001) compared to patients with low dyspnoea. The exacerbation rates among these patients are displayed in Fig. 3 .
Similar proportions of patients in both groups (mMRC C2 vs. mMRC\2) had at least one PCP consultation (84.6% vs. 85.7%; P = 0.5898) but higher proportions of moderate-to-severe dyspnoeic patients had at least one specialist consultation (90.3% vs.
78.0%; P\0.0001). The annual rate of physician consultation was higher among patients with moderate-to-severe dyspnoea, both for primary and secondary care consultations (P\0.0001 for both; Fig. 4 ).
Moderate-to-severe dyspnoeic patients also had higher proportions of other HCRU, notably pulmonary rehabilitation, long-term oxygen therapy, and need for professional care (all P\0.0001; Table 2 ). In the full cohort, propensity matching on the baseline demographics and clinical parameters other than mMRC scores resulted in 762 patients with mMRC C2 and 762 matched patient profiles (400 unique patients) Fig. 3 Exacerbation rates in the previous year among unmatched no-to-mild and moderate-to-severe dyspnoea patients diagnosed with chronic obstructive pulmonary disease in the European countries studied. Rates based on weighted data. }P\0.0001; § P = 0.0114. A&E Accident and emergency, OCS oral corticosteroids, mMRC Modified Medical Research Council dyspnoea scale Fig. 4 Physician consultation rates in the previous year among unmatched no-to-mild and moderate-to-severe dyspnoea patients diagnosed with chronic obstructive pulmonary disease in the European countries studied.
Rates based on weighted data. }P\0.0001. mMRC Modified Medical Research Council dyspnoea scale, PCP primary care physician from a cohort of 919 available patients with mMRC\2. All covariates were adequately balanced post-matching (Table 1 ). In this propensity-matched cohort, the total annual COPD management cost was more than twofold higher among patients with moderate-to-severe dyspnoea compared to patients with no-to-mild dyspnoea (€4372 vs. €2031; P\0.0001). The sensitivity analysis produced a C of 2. 3 
DISCUSSION
This study estimated the prevalence of dyspnoea among patients actively consulting due to their COPD, and its association with health status and costs in five European countries. Results showed that across all countries nearly half of the patients diagnosed with COPD suffered from moderate-to-severe dyspnoea. The moderate-to-severe dyspnoeic patients had worse general and COPD-related health status and impaired sleep compared to The healthcare utilities in our study for the no-to-mild dyspnoeic patient group (mMRC\2) were identical at 0.88 but were substantially higher for patients with moderate-to-severe dyspnoea (mMRC C2; 0.17/0.29 vs. 0.67). This may be attributable to differing definitions of moderate-to-severe dyspnoea in our study (mMRC C2) compared to the Punekar study (mMRC = 4). Another study by Mullerova and colleagues [8] found that the presence of even mild dyspnoea (as compared to no dyspnoea) to be associated with more disease burden and higher frequency of comorbidities and a study by Kessler and others [4] found dyspnoea physical component [41] [42] [43] .
The Confronting COPD survey estimated the burden of COPD on patients globally [44] . The economic sub-analysis of confronting COPD survey indicated that costs ranged from €590
(direct cost: €395; indirect cost: €195) in patients with mild dyspnoea to €4670 (direct cost: €3036; indirect cost: €1634) in patients with severe dyspnoea in the UK [44] . The corresponding costs ranged from €441 in patients with mild dyspnoea to €6365 in patients with severe dyspnoea in Italy [45] . In Moreover, the prevalence of dyspnoea and distribution of airflow limitation severity was similar to those observed in other studies conducted in general practice [43] . While minimal exclusion criteria governed the selection of physicians (mainly relating to the necessity of participating physicians to see a minimum volume of patients and be actively involved in patient management and treatment decisions), physician inclusion was likely influenced by their willingness to take part, and practical considerations of geographical location. These results were weighted to make them more generalizable to the COPD population in the specific country in which data were collected. In some instances, this resulted in negative CIs on costs due to an assumption of normality in calculating the 95% CIs for right-skewed cost data. 
